Regeneron Pharmaceuticals says it will acquire 23andMe’s assets, including its Personal Genome Service, for $256M, set to close in Q3, in the bankruptcy auction (Dean Seal/Wall Street Journal)

Dean Seal / Wall Street Journal:
Regeneron Pharmaceuticals says it will acquire 23andMe's assets, including its Personal Genome Service, for $256M, set to close in Q3, in the bankruptcy auction  —  Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe's assets  —  Regeneron Pharmaceuticals …